List of Mydayis drug patents

Mydayis is owned by Takeda Pharms Usa.

Mydayis contains Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate.

Mydayis has a total of 3 drug patents out of which 0 drug patents have expired.

Mydayis was authorised for market use on 20 June, 2017.

Mydayis is available in capsule, extended release;oral dosage forms.

Mydayis can be used as treatment of attention deficit hyperactivity disorder.

The generics of Mydayis are possible to be released after 24 August, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts
May, 2023

(3 months from now)

US9173857 TAKEDA PHARMS USA Controlled dose drug delivery system
May, 2026

(3 years from now)

US8846100 TAKEDA PHARMS USA Controlled dose drug delivery system
Aug, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
M Sep 13, 2022
Pediatric Exclusivity (PED) Mar 13, 2023

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 20 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of MYDAYIS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic